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Abstract: Bone metastasis from breast cancer often cause signiﬁ  cant morbidity including pain, 
impaired mobility, pathological fracture, and spinal cord compression. Bisphosphonates play 
an important role in preventing these skeletal related events and are the standard of care for 
patients with bone metastasis from breast cancer. Ibandronate is a highly potent bisphosphonate 
available in both intravenous and oral preparations. It has been shown in clinical trials to be 
effective in reducing skeletal complications and also signiﬁ  cantly improve quality of life up to 
96 weeks. Unlike other intravenous bisphosphonates, ibandronate has minimal renal toxicity, 
allowing safe outpatient administration, reducing the need for hospital attendance and safety 
monitoring. Early trials have shown ibandronate may also be effective in high doses for palliation 
of opioid-resistant pain from bone metastasis, and as a second-line agent in patients developing 
a skeletal complication whilst receiving another bisphosphonate.
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Introduction
Metastatic bone disease is prevalent in advanced cancer. Typically, 65%–75% of 
patients with breast cancer develop skeletal metastases, the onset of which can have 
profound effects on quality of life and functional status (Diel et al 2004). Bone metas-
tases cause signiﬁ  cant morbidity, including bone pain, impaired mobility, pathological 
fracture, and spinal cord or nerve root compression (Body et al 2000; Coleman 2001) 
Since patients with breast cancer and bone metastases survive on average for 2.5 years 
(Diel et al 2000), treatment strategies must be well tolerated during long-term use.
A balance between the action and activity of osteoclasts and osteoblasts maintains 
bone strength and integrity. The adult skeleton is continually remodeling; the osteoclast 
ﬁ  rst removes old bone and then new bone is formed by the osteoblast. Metastatic breast 
cancer cells release hormones, which cause bone destruction by inducing osteoclast 
activation. This leads to the formation of lytic metastasis. These hormones include 
parathyroid related peptide, prostaglandins, tumour necrosis factor and macrophage 
colony stimulating factor all which act by increasing the expression of receptor activator 
of nuclear factor-κβ ligand (RANKL) (Grano et al 2000). The bone that is resorbed 
by the activated osteoclast is a rich source of inactive growth factors. When released 
into the bone microenvironment these growth factors provide stimulus for surrounding 
breast cancer cells (Pfeilschifter and Mundy 1987).
Traditionally the main treatment for bone metastases from breast cancer has been che-
motherapy or endocrine therapy. External beam radiation is indicated for painful localized 
sites. Bisphosphonates have become an additional treatment option. This class of drugs 
effectively reduces the risk of skeletal complications from metastatic bone disease, and 
is currently considered to be the standard of care for most patients with bone metastases 
from breast cancer (Hultborn et al 1999; Rosen et al 2001; Pavlakis and Stockler 2002; Therapeutics and Clinical Risk Management 2008:4(2) 454
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Hillner et al 2003; Lipton 2003). In patients with metastatic 
breast cancer bisphosphonate treatment does not appear to 
inﬂ  uence survival (Pavlakis and Stockler 2002).
Bisphosphonates are selectively concentrated in bone 
where they utilize a number of mechanisms to inhibit bone 
resorption. Firstly, they bind avidly to the bone mineral at 
sites of active metabolism and, in doing so, inhibit the disso-
lution of hydroxyapatite crystals (Russell et al 1999). Clodro-
nate (Bonefos®; Schering AG, Berlin, Germany; and Ostac®, 
Loron®, F.Hoffmann-La Roche Ltd, Basel, Switzerland) is a 
non-nitrogen-containing bisphosphonate and works through 
this mechanism of action. Nitrogen-containing bisphos-
phonates (N-BPs) which include pamidronate (Aredia®; 
Novartis Pharmaceutical Corp.; East Hanover, NJ, USA), 
alendronate (Fosamax®; Merck and Company, Inc.; West 
Point, PA, USA), ibandronate, risedronate (Actonel®; Proctor 
and Gamble Pharmaceuticals, Inc.; Cincinnati, OH, USA), 
and zoledronic acid (Zometa®; Novartis Pharmaceuticals 
Corp.) also inhibit osteoclast activity and survival through a 
number of other mechanisms. The N-BPs are internalized by 
osteoclasts and inhibit a key enzyme important in regulation 
of cell survival, proliferation, and cytoskeletal organization 
(Zhang and Casey 1996; Luckman et al 1998; Oliff 1999; 
Russell et al 1999). The inhibition of this enzyme also leads 
to morphological changes in the osteoclast rendering it unable 
to form a rufﬂ  ed border on the bone surface, an essential step 
in osteoclast-mediated bone resorption (Luckman, Hughes 
et al 1998). More recently N-BPs have been found to directly 
induce apoptosis in the osteoclast (Monkkonen et al 2006). 
Preclinical trials have suggested that, in addition to anti-
osteoclastic activity, bisphosphonates may also exhibit direct 
anti-tumor activity. The mechanisms of action are still being 
investigated. In vitro studies and animal studies have shown 
treatment with bisphosphonates decreases tumor burden 
in bone (Hiraga et al 2001; Daubine et al 2007). Studies 
examining the effect of bisphosphonate treatment on visceral 
metastasis have been conﬂ  icting, some showing a reduction 
in tumor burden and others increased activity (Nobuyuki H 
2001; Michigami et al 2002). This direct effect on tumor cells 
has not corresponded with a survival advantage.
Four bisphosphonates are available for treatment of bone 
metastasis in metastatic breast cancer (MBC): clodronate, 
pamidronate, zoledronic acid, and ibandronate. All four 
drugs have been shown in clinical studies to be effective in 
palliating pain, reducing skeletal related events and improv-
ing quality of life. American Society of Clinical Oncology 
consensus guidelines suggest commencing bisphosphonate 
therapy in patients with bone metastases and evidence of bony 
destruction on plain radiograph, CT, or MRI. At this time, 
there is no role for commencing bisphosphonate therapy in 
patients with an abnormal nuclear bone scan only (Hillner et al 
2003). Bisphosphonates used for treatment of bony metasta-
sis from breast cancer have different dosage and scheduling 
(Table 1). The optimal duration of bisphosphonate therapy for 
MBC is not known and guidelines suggest life-long therapy 
once bisphosphonates are commenced. Similarly, the optimal 
frequency of administration of long-term bisphosphonate 
therapy is not known. Consensus guidelines suggest standard 
dosing continue indeﬁ  nitely in the absence of toxicity.
Although intravenous bisphosphonates have established 
efﬁ  cacy in patients with bone metastases, the intravenous 
route is cumbersome, especially for long-term use that 
requires administration in hospital or home nurse visits. 
Several studies have shown that patients prefer oral over 
intravenous therapy (Liu et al 1997; Paley et al 2005). 
Bisphosphonates such as pamidronate and zoledronic acid 
have the potential to cause renal toxicity, especially when 
they are administered too quickly and/or at an excessive dose 
(Ali et al 2001; Banerjee et al 2003; Chang et al 2003). Regu-
lar serum creatinine monitoring is required before each infu-
sion, which increases the demands on healthcare resources 
(NovartisPharma). Oral bisphosphonates such as clodronate 
are more convenient than intravenous treatment, yet the 
efﬁ  cacy of such oral bisphosphonates is often considered 
inferior to intravenous agents (Major et al 2000). In addi-
tion, oral clodronate can be associated with gastrointestinal 
adverse effects and suboptimal compliance due to the large 
tablets and complex dosing regimens (Paterson et al 1993; 
Atula et al 2003). The ideal palliative bisphosphonate therapy 
should therefore combine oral convenience and intravenous 
Table 1 Dosage and scheduling of bisphosphonates used for treatment of bony metastasis from breast cancer
Bisphosphonate  Standard dosage  Route of administration  Duration of infusion  Frequency of administration
 (mg)
Clodronate 1600–3200  oral  NA  twice  daily
Ibandronate 50  oral  NA  daily
Ibandronate  6  intravenous  1–2 hours  every 3–4 weeks
Pamidronate  90  intravenous  2 hours  every 3–4 weeks
Zoledronic acid  4  intravenous  15 minutes  every 3–4 weeksTherapeutics and Clinical Risk Management 2008:4(2) 455
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efﬁ  cacy with maximum safety. Ibandronate (ibandronic acid) 
is a single nitrogen-containing bisphosphonate available as 
intravenous and oral formulations.
Efﬁ  cacy of ibandronate
The efﬁ  cacy of ibandronate in reducing skeletal related events 
(SREs) has been assessed in three placebo controlled, phase 
III trials in patients with bone metastasis and MBC. In all 
three trials, ibandronate reduced the relative risk of SREs by 
approximately 40% (Body et al 2003b; Body et al 2004a).
In the study of intravenous ibandronate, 466 patients were 
randomized to either placebo or 2 mg or 6 mg of ibandronate 
3–4 weekly, for up to 2 years. The primary endpoint of the 
study was the number of 12-week periods with new bone 
complications expressed as the skeletal morbidity period rate 
(SMPR). New bone complications were deﬁ  ned as vertebral 
fractures, pathological non-vertebral fractures, radiotherapy, or 
surgery for bone complications (pain or impending fractures). 
Secondary outcomes were bone pain and safety. Patients in the 
6 mg ibandronate group showed a reduction in SMPR of 20% 
compared with placebo (1.19 vs 1.48; p = 0.004). There was 
also a statistically signiﬁ  cant decrease in the number of new 
bone events (2.65 events per patient vs 3.64; p = 0.032) and 
time to ﬁ  rst bone event from randomization (50.6 weeks vs 
33.1; p = 0.018) between ibandronate 6 mg and placebo. Bone 
pain was also signiﬁ  cantly improved in patients receiving 6 
mg ibandronate with a rapid reduction in their pain score that 
persisted throughout the study. Ibandronate was well tolerated 
with a safety proﬁ  le similar to placebo and no renal toxicity 
documented (Body et al 2003a).
Oral ibandronate was evaluated using pooled data from 
2 identical clinical trials prespeciﬁ  ed in the individual trial 
protocols. Five hundred and forty-six patients received 
oral ibandronate 20 mg, 50 mg, or placebo daily for up to 2 
years. Only the results of the 50 mg dose vs placebo were 
reported, which is the recommended dose. The primary 
endpoint was SMPR. Patients taking oral ibandronate were 
found to have a signiﬁ  cantly lower SMPR than those taking 
placebo (0.95 vs 1.18; p = 0.004) and there was a decrease 
in mean number of skeletal events per patient (1.15 vs 1.85; 
p = 0.008) (Body et al 2004b).
A phase III trial comparing oral ibandronate and i.v. zole-
dronic acid has been conducted using bone turnover mark-
ers as a surrogate measurement of bisphosphonate efﬁ  cacy 
(Body et al 2007). Two hundred and seventy-ﬁ  ve patients 
with bone metastasis and metastatic breast cancer received 
either 4 mg zoledronic acid every 4 weeks or 50 mg/day of 
oral ibandronate for 12 weeks. The primary endpoint was 
mean percentage change in serum levels of cross-linked 
C-terminal telopeptide of type I collagen (S-CTX) at week 12 
reﬂ  ecting the rate of bone resorption. Both bisphosphonates 
signiﬁ  cantly reduced S-CTX from baseline and noninferiority 
was demonstrated between the two treatments. Ibandronate 
was better tolerated with less pyrexia and bone pain. There 
are currently no published trials prospectively comparing 
the efﬁ  cacy of pamidronate or zoledronic acid to ibandro-
nate in reducing SREs in metastatic breast cancer. However 
randomized phase III trials are in progress.
Palliation of symptoms 
with ibandronate
The use of both oral and intravenous ibandronate is well 
established as an effective treatment for the palliation of pain 
from bone metastasis. Compared with placebo, 6 mg of iban-
dronate i.v. administered 3–4 weekly signiﬁ  cantly improved 
bone pain, quality of life, and functional assessments 
(p   0.05) for up to 96 weeks after treatment commenced. 
This improvement was statistically signiﬁ  cant in all domains 
assessed including physical, social and emotional functioning 
and global health status (Diel, Body et al 2004). This pro-
longed beneﬁ  t with ibandronate contrasts with pamidronate 
where long-term treatment did not signiﬁ  cantly reduce bone 
pain after 1–2 years of treatment (Hortobagyi et al 1998). 
Oral ibandronate has also been shown to improve bone pain 
and quality of life compared with placebo (Body et al 2004a). 
A similar study with 435 patients comparing oral ibandronate 
50 mg with placebo showed a trend towards improved pain 
scores and decreased analgesic use (p = 0.074) but did not 
reach statistical signiﬁ  cance (Tripathy et al 2004).
Bisphosphonates can take up to 12 weeks to achieve their 
maximal analgesic effect. Studies have assessed whether 
higher doses of bisphosphonate can achieve earlier pain relief. 
Ibandronate is ideally suited for this purpose having a more 
favorable safety proﬁ  le than either pamidronate or zoledronic 
acid. Eighteen patients with a variety of malignant tumours, 
including metastatic breast cancer, and a history of moderate 
to severe opioid-resistant metastatic bone pain received non-
standard treatment with 4 mg of ibandronate administered i.v. 
(2-hour infusion) for 4 consecutive days (16 mg total dose). 
All patients had baseline opiate use of 400 mg/day. Intensive 
ibandronate treatment signiﬁ  cantly reduced bone pain scores 
within 7 days (p   0.001) and this was maintained over the 
6-week study period. Overall quality of life, patient func-
tioning, and performance status also improved signiﬁ  cantly 
(p   0.05). There was no evidence of renal toxicity in the 18 
patients treated (Mancini et al 2004).Therapeutics and Clinical Risk Management 2008:4(2) 456
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A recent phase II study examined the role of sec-
ond-line ibandronate in patients who suffered an SRE or 
progressive metastatic disease whilst receiving clodronate 
or pamidronate. Patients received 50 mg oral ibandronate 
for 12 weeks. A palliative response was deﬁ  ned a priori 
as a two-unit reduction in pain score. Thirty patients with 
metastatic breast cancer completed the study. At 12 weeks 
patients achieved a signiﬁ  cant improvement in pain con-
trol (OR 0.41; p = 0.028), 46% of those being a palliative 
response and thus clinically relevant (Clemons et al 2008). 
This ﬁ  nding needs further investigation in the setting of a 
randomized trial, however, if conﬁ  rmed, it may mean that a 
variety of bisphosphonates can be used through the course 
of a patient’s disease.
Safety of ibandronate
Bisphosphonate therapy in metastatic breast cancer is used 
as palliative treatment therefore toxicity and tolerability is 
a major consideration. These effects differ according to the 
route of administration and the drug used. The main adverse 
events associated with bisphosphonate therapy are acute-
phase reactions, gastrointestinal toxicity, renal toxicity, and, 
rarely, osteonecrosis of the jaw.
Flu-like symptoms, joint pain, and pyrexia are all tran-
sient acute phase reactions that can occur after bisphos-
phonate infusions. Two trials have compared the safety of 
ibandronate with that of zoledronic acid. One administered an 
initial dose of intravenous ibandronate followed by daily oral 
treatment; the other used oral ibandronate alone, compared 
with intravenous zoledronic acid administered 3–4 weekly. 
Patients receiving intravenous ibandronate experienced less 
ﬂ  u like symptoms than those treated with zoledronic acid 
(13% vs 26%) (Bergstrom et al 2006). The incidence of ﬂ  u-
like symptoms was, not surprisingly, lower in the patients 
receiving oral ibandronate compared with zoledronic acid 
(2% vs 27%) (Body et al 2006).
Oral bisphosphonates have typically been associated 
with gastrointestinal toxicity. Clodronate, due to its low 
bioavailability, is a large tablet administered twice daily. 
When administered for 2 years in patients with breast can-
cer it was associated with increased gastrointestinal toxic-
ity compared with placebo (57% vs 45%: p   0.05). This 
toxicity was signiﬁ  cant for both upper gastrointestinal side 
effects such as esophagitis, mucositis, and nausea as well 
as diarrhea (Powles et al 2002). In the pooled analysis of 
oral ibandronate, patients receiving ibandronate were twice 
as likely to experience gastrointestinal side effects as those 
receiving placebo (14.6% vs 7.6%) (Body et al 2004b). It 
appears that oral ibandronate may cause less gastrointestinal 
toxicity than clodronate, although no direct comparison has 
been made.
Clinically signiﬁ  cant rises in serum creatinine are rare 
among patients treated with i.v. bisphosphonates. Both 
pamidronate and zoledronic acid have been associated with 
acute and chronic nephrotoxicity (Chang et al 2003; Szeto 
and Chow 2005). Clinical guidelines suggest monitoring of 
serum creatinine prior to every treatment with either of these 
drugs, potentially adding to both the cost and time taken to 
administer treatment (Hillner et al 2003). Renal toxicity 
may not be a class effect with intravenous bisphosphonates. 
A study examining the safety of intravenous ibandronate 
administered for up to 4 years found no clinically relevant 
renal adverse events nor a change in baseline serum creatinine 
(Pecherstorfer et al 2006). Similarly, in patients receiving 
oral ibandronate for up to 4 years, there were no adverse renal 
events and serum creatinine remained stable throughout the 
duration of treatment (McLachlan et al 2006).
Osteonecrosis of the jaw (ONJ) is a rare but well estab-
lished adverse event associated with all classes of bisphos-
phonates. Patients treated with high potency bisphosphonates 
or over a long period of time are believed to be at greater risk 
of developing ONJ (Bamias et al 2005) and current practice 
guidelines suggest dental examination and tooth extraction 
prior to commencement of bisphosphonate therapy. Patients 
should also avoid elective dental surgery once potent bisphos-
phonates are commenced (Hillner et al 2003). An Australian 
study has recently estimated the frequency of bisphospho-
nate associated ONJ. In patients with metastatic cancer to 
bone they found a relative frequency of ONJ of 1 in 87–114 
(0.88%–1.14%), this increased dramatically if extractions 
were performed to 1 in 11–15 (6.67%–9.1%). The median 
time to ONJ in all patients was 12 months for zoledronic acid, 
24 months for pamidronate, and 24 months for alendronate 
(Mavrokokki et al 2007). The International Myeloma Foun-
dation collected similar data in the United States from 1203 
respondents: 904 had myeloma and 299 breast cancer. With 
censoring of data at 36 months they found ONJ developed in 
10% of 211 patients receiving zoledronic acid, compared with 
4% of 413 patients receiving pamidronate (p = 0.002 by the 
log-rank test) (Durie and Crowley 2005). Due to the design 
of these studies both may overestimate the incidence of ONJ; 
however, it is a side-effect that both patient and clinician need 
to be mindful of. Oral bisphosphonates are associated with a 
decreased risk of ONJ compared with intravenous prepara-
tions. A study using oral surgery as a surrogate marker for 
ONJ found no association between oral bisphosphonate use Therapeutics and Clinical Risk Management 2008:4(2) 457
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and jaw surgery (Pazianas et al 2007). Case reports of ONJ 
associated with oral bisphosphonates, including ibandronate, 
are emerging (Malden and Pai 2007).
Cost effectiveness
In removing the need for hospital attendance and regular safety 
monitoring, oral bisphosphonates may be more cost effective 
than intravenous administration (saving time for nurses and 
patients and reducing the use of hospital resources) (Navarro 
et al 2002). The cost-effectiveness of oral ibandronate com-
pared with other intravenous bisphosphonates in the UK 
healthcare setting has recently been reported (De Cock et al 
2005). This analysis found oral ibandronate to be more cost 
effective treatment than intravenous zoledronic acid or intrave-
nous pamidronate in patients with metastatic breast cancer.
Conclusion
Clodronate, ibandronate, pamidronate, and zoledronic acid 
are all effective in reducing SREs and improving quality of 
life in patients with metastatic breast cancer. This class of 
drugs has been adopted as the standard of care for patients 
with bone metastasis from breast cancer (Hillner et al 2003). 
No bisphosphonate has an impact on survival. Consequently, 
efﬁ  cacy, both in reducing SREs and palliating pain, ease 
of administration, and the side effect proﬁ  le are important 
considerations in bisphosphonate choice. Ibandronate is a 
potent bisphosphonate, with similar efﬁ  cacy to zoledronic 
acid in reducing markers of bone resorption and has the 
beneﬁ  t of both oral and intravenous routes of administration. 
Its safety proﬁ  le is superior to that of both pamidronate and 
zoledronic acid, with minimal renal toxicity and less acute 
phase reactions. Unlike pamidronate, ibandronate effectively 
palliates pain from bone metastasis for as long as 2 years and 
thus has a durable impact on patient’s quality of life. New 
developments examining ibandronate’s role as a second-line 
bisphosphonate or at high doses to palliate opioid-resistant 
pain need further evaluation in clinical trials.
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